Day : Friday
Date: 9/15/2006

Time: 08:56:23

PALM INTRANET

Inventor Information for 10/822975

Inventor Name	City	State/Country
GRIFFITH, DAVID A.	OLD SAYBROOK	CONNECTICUT
HAMMOND, MARLYS	BLUE BELL	PENNSYLVANIA

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign D

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11  KOREAPAT updates resume
 NEWS  6  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  8  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 10  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 11  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14  FSTA enhanced with Japanese patents
 NEWS 14  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11  CA/CAplus enhanced with more pre-1907 records

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:42:50 ON 15 SEP 2006

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21
```

FILE 'REGISTRY' ENTERED AT 18:43:01 ON 15 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1
DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available. Please contact CAS Customer Care
(http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10822975y.str

chain nodes :
10 11 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14 8-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-11

G1:Cy,Cb,Hy

G2:C,H,O

G3:O,N,C

G4:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cy,Cb,Hy

G2 C,H,O

G3 O,N,C

G4 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 18:43:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1441 TO ITERATE

100.0% PROCESSED 1441 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 26543 TO 31097
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 18:43:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 27542 TO ITERATE

100.0% PROCESSED 27542 ITERATIONS 216 ANSWERS
SEARCH TIME: 00.00.01

L3 216 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 18:43:29 ON 15 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 5 L3

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	167.61

STN INTERNATIONAL LOGOFF AT 18:43:43 ON 15 SEP 2006

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11   KOREAPAT updates resume
 NEWS  6  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  8  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 10  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 11  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14   FSTA enhanced with Japanese patents
 NEWS 14  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11   CA/CAplus enhanced with more pre-1907 records

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:54:02 ON 15 SEP 2006

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 09:54:15 ON 15 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1
DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10822975z.str





chain nodes :
10 11 14 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14 4-18 8-10 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 4-5 4-18 5-6 5-7 6-9 7-8 8-9 8-10 9-11

G1:Cy,Cb,Hy

G2:C,H,O

G3:O,N,C

G4:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 14:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cy,Cb,Hy

G2 C,H,O

G3 O,N,C

G4 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 09:54:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1068 TO ITERATE

100.0% PROCESSED 1068 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19400 TO 23320
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:54:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20959 TO ITERATE

100.0% PROCESSED 20959 ITERATIONS 93 ANSWERS
SEARCH TIME: 00.00.01

L3 93 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 09:54:53 ON 15 SEP 2006

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 13 Sep 2006 (20060913/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 5 L3

=> d l4 ibib hitstr abs 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1341997 CAPLUS
DOCUMENT NUMBER: 144:233032
TITLE: New bicyclic cannabinoid receptor-1 (CB1-R) antagonists
AUTHOR(S): Carpino, Philip A.; Griffith, David A.; Sakya, Subas; Dow, Robert L.; Black, Shawn C.; Hadcock, John R.; Iredale, Philip A.; Scott, Dennis O.; Fichtner, Michael W.; Rose, Colin R.; Day, Robert; Dibrino, Joseph; Butler, Mary; DeBartolo, Demetria B.; Dutcher, Darrin; Gautreau, Denise; Lizano, Jeff S.; O'Connor, Rebecca E.; Sands, Michelle A.; Kelly-Sullivan, Dawn; Ward, Karen M.
CORPORATE SOURCE: Pfizer Global Research and Development-Groton Laboratories, Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(3), 731-736
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 784193-08-4P 876405-94-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as cannabinoid receptor-1 (CB1-R) antagonists)
RN 784193-08-4 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 876405-94-6 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 3-(2-chlorophenyl)-2-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)



GI



I

AB A series of conformationally constrained bicyclic derivs. derived from SR141716 was prepared and evaluated as hCB1-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one derivative led to the identification of I [R = H, Me] with oral activity in rodent feeding models. Replacement of the PP group in I [R = H] with other bicyclic groups resulted in a loss of binding affinity.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:905619 CAPLUS
DOCUMENT NUMBER: 141:379939
TITLE: Preparation of pyrazolo[4,3-d]pyrimidin-7-one and pyrazolo[3,4-c]pyridin-7-one compounds as cannabinoid receptor ligands

INVENTOR(S): Carpino, Philip A.; Griffith, David A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214838	A1	20041028	US 2004-822988	20040412
CA 2523205	AA	20041104	CA 2004-2523205	20040413
WO 2004094417	A1	20041104	WO 2004-IB1262	20040413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622902	A1	20060208	EP 2004-727068	20040413
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009689	A	20060418	BR 2004-9689	20040413
NL 1026029	A1	20041027	NL 2004-1026029	20040423
NL 1026029	C2	20050705		

PRIORITY APPLN. INFO.: US 2003-464916P P 20030423
WO 2004-IB1262 W 20040413

OTHER SOURCE(S): MARPAT 141:379939
IT 784193-08-4P 784193-09-5P 784193-10-8P
784193-11-9P 784193-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[4,3-d]pyrimidin-7-one and pyrazolo[3,4-c]pyridin-7-one compds. as cannabinoid receptor ligands)
RN 784193-08-4 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 784193-09-5 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-2,4-dihydro-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 784193-10-8 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 784193-11-9 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 784193-17-5 CAPLUS
CN 7H-Pyrazolo[3,4-c]pyridin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,6-dihydro- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. I [A = N, CR2 (wherein R2 = H, alkyl, haloalkyl, alkoxy); R0, R1 = (un)substituted (hetero)aryl; R3 = H, (un)substituted alkyl, alkoxy; R4 = alkyl, aryl, heteroaryl, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared E.g., a 2-step synthesis of II, starting from 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid, was given. All the exemplified compds. were tested in the CB-1 receptor binding assay and provided a range of binding activities from 0.09 to 453 nM. The pharmaceutical composition comprising the compound I is claimed.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:905618 CAPLUS
DOCUMENT NUMBER: 141:379938
TITLE: Preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compounds as cannabinoid receptor ligands
INVENTOR(S): Griffith, David A.; Hammond, Marlys
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214837	A1	20041028	US 2004-822975	20040412
CA 2520842	AA	20041111	CA 2004-2520842	20040420
WO 2004096801	A1	20041111	WO 2004-IB1418	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1622904	A1	20060208	EP 2004-728385	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009634	A	20060425	BR 2004-9634	20040420
NL 1026030	A1	20041101	NL 2004-1026030	20040423
NL 1026030	C2	20050705		

PRIORITY APPLN. INFO.: US 2003-464918P P 20030423
US 2004-540048P P 20040129
WO 2004-IB1418 W 20040420

OTHER SOURCE(S): MARPAT 141:379938

IT 784208-41-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)

RN 784208-41-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropoxy)-5-methyl- (9CI) (CA INDEX NAME)



IT 784206-67-3P 784206-71-9P 784206-76-4P
784206-77-5P 784207-36-9P 784207-56-3P
784207-57-4P 784207-58-5P 784207-59-6P
784207-60-9P 784207-61-0P 784207-62-1P
784207-63-2P 784207-64-3P 784207-65-4P
784207-66-5P 784207-67-6P 784207-68-7P
784207-69-8P 784207-70-1P 784207-71-2P
784207-72-3P 784207-73-4P 784207-74-5P
784207-75-6P 784207-76-7P 784207-77-8P
784207-78-9P 784207-79-0P 784207-80-3P
784207-81-4P 784207-82-5P 784207-83-6P
784207-84-7P 784207-85-8P 784207-86-9P
784207-87-0P 784207-88-1P 784207-89-2P
784207-90-5P 784207-91-6P 784207-92-7P
784207-93-8P 784207-94-9P 784207-95-0P
784208-00-0P 784208-01-1P 784208-05-5P
784208-32-8P 784208-33-9P 784208-34-0P
784208-35-1P 784208-36-2P 784208-37-3P
784208-38-4P 784208-39-5P 784208-40-8P
784208-42-0P 784208-43-1P 784208-44-2P
784208-45-3P 784208-46-4P 784208-47-5P
784208-49-7P 784208-50-0P 784208-51-1P
784208-52-2P 784208-53-3P 784208-54-4P
784208-65-7P 784208-66-8P 784208-67-9P
784208-68-0P 784208-69-1P 784208-70-4P
784208-71-5P 784208-72-6P 784208-73-7P
784208-74-8P 784208-75-9P 784208-76-0P
784208-77-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)

RN 784206-67-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 784206-71-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 784206-76-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 784206-77-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 784207-36-9 CAPLUS
CN Cyclohexanol, 4-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-56-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 784207-57-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 784207-58-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(3-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 784207-59-6 CAPLUS
CN Cyclopentanecarboxylic acid, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-60-9 CAPLUS
CN Cyclopentanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-61-0 CAPLUS
CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-62-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cycloheptyl- (9CI) (CA INDEX NAME)



RN 784207-63-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cyclobutyl- (9CI) (CA INDEX NAME)



RN 784207-64-3 CAPLUS
CN 1,3-Propanediol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 784207-65-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 784207-66-5 CAPLUS
CN Cyclopentanemethanol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784207-67-6 CAPLUS
CN 1-Propanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 784207-68-7 CAPLUS
CN 1,4-Pentanediamine, N4-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 784207-69-8 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 784207-70-1 CAPLUS
CN Benzenepropanol, β-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784207-71-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



RN 784207-72-3 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 784207-73-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 784207-74-5 CAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(phenylmethyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-75-6 CAPLUS

CN Pyrrolidine, 1-[(2S)-2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-76-7 CAPLUS
CN Phenol, 4-[(2S)-2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-77-8 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(1R)-1-cyclohexylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-78-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(1R)-1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-79-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(1S)-1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784207-80-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 784207-81-4 CAPLUS
CN 1H-Inden-2-ol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2,3-dihydro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784207-82-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-methyl-2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 784207-83-6 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 784207-84-7 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 784207-85-8 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 784207-86-9 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[6-(1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 784207-87-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-[6-(1-azetidinyl)-3-pyridinyl]-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 784207-88-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 784207-89-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 784207-90-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 784207-91-6 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 784207-92-7 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(1H-benzimidazol-2-ylmethyl)-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 784207-93-8 CAPLUS
CN 2-Propanol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784207-94-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 784207-95-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 784208-00-0 CAPLUS
CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 784208-01-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)



RN 784208-05-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784208-32-8 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 784208-33-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 784208-34-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[[1-(diphenylmethyl)-3-azetidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 784208-35-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-36-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-(1-methylethyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-37-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-methoxyphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-38-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-ethoxy-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 784208-39-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 784208-40-8 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluorobutoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 784208-42-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-3-(4-methoxyphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-43-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-bromophenyl)-7-(2,2-difluoropropoxy)-3-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 784208-44-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-(4-bromophenyl)-2-(2-chlorophenyl)-7-(2,2-difluoropropoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 784208-45-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-7-(2,2-difluoropropoxy)-3-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 784208-46-4 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-7-(1-methylethoxy)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 784208-47-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chloro-4-methylphenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 784208-49-7 CAPLUS
CN 2H-Pyrazolo[3,4-c]pyridine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-50-0 CAPLUS
CN Benzonitrile, 2-[3-(4-chlorophenyl)-5-methyl-7-(2,2,2-trifluoroethoxy)-2H-pyrazolo[4,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 784208-51-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-ethoxy- (9CI) (CA INDEX NAME)



RN 784208-52-2 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-propoxy- (9CI) (CA INDEX NAME)



RN 784208-53-3 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 7-butoxy-2-(2-chlorophenyl)-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 784208-54-4 CAPLUS
CN 2H-Pyrazolo[3,4-c]pyridine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 784208-65-7 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 784208-66-8 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 784208-67-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)- (9CI) (CA INDEX NAME)



RN 784208-68-0 CAPLUS
CN Cyclopentanecarboxylic acid, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784208-69-1 CAPLUS
CN Cyclopentanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784208-70-4 CAPLUS
CN Cyclohexanol, 2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 784208-71-5 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(2,6-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 784208-72-6 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 784208-73-7 CAPLUS
CN Pyrrolidine, 1-[2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 784208-74-8 CAPLUS

CN Phenol, 4-[2-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 784208-75-9 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-(1-cyclohexylethyl)- (9CI) (CA INDEX NAME)



RN 784208-76-0 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-N-[1-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)





RN 784208-77-1 CAPLUS
CN 1H-Inden-2-ol, 1-[[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2,3-dihydro- (9CI) (CA INDEX NAME)



IT 784193-08-4P 784193-10-8P 784193-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)
RN 784193-08-4 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 784193-10-8 CAPLUS
CN 7H-Pyrazolo[4,3-d]pyrimidin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)



RN 784193-17-5 CAPLUS
CN 7H-Pyrazolo[3,4-c]pyridin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,6-dihydro- (9CI) (CA INDEX NAME)



GI



AB The title compds. I [A = N, CR2 (wherein R2 = H, alkyl, haloalkyl, alkoxy); R0, R1 = (un)substituted (hetero)aryl; R3 = H, alkyl, haloalkyl,

alkoxy; R4 = (un)substituted pyrrolidino, piperidino, piperazino, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared Thus, reacting 7-chloro-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[3,4-c]pyridine with 4-ethylaminopiperidine-4-carboxylic acid amide (prepns. given) afforded 78% II. All the exemplified compds. (over 190) were tested in the CB-1 receptor binding assay and showed a range of binding activities from 0.2 nM to 1.6 μM. The pharmaceutical composition comprising the compound I is claimed.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:147157 CAPLUS
DOCUMENT NUMBER: 140:321638

TITLE: Imino-C-nucleoside Synthesis: Heteroaryl Lithium Carbanion Additions to a Carbohydrate Cyclic Imine and Nitrone

AUTHOR(S): Evans, Gary B.; Furneaux, Richard H.; Hausler, Herwig; Larsen, Janus S.; Tyler, Peter C.
CORPORATE SOURCE: Carbohydrate Chemistry, Industrial Research Limited, Lower Hutt, N. Z.

SOURCE: Journal of Organic Chemistry (2004), 69(6), 2217-2220
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:321638

IT 607389-23-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of imino-C-nucleosides via heteroaryl lithium carbanion addns. to a carbohydrate cyclic imine and nitrone)

RN 607389-23-1 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-[(3aS,4S,6R,6aR)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrol-4-yl]-7-methoxy-2-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Promotion by Lewis acid of the addition of some aryllithiums to a carbohydrate-based imine, which has allowed a more facile synthesis of some imino-C-nucleoside analogs, is described. Use of the corresponding nitrone does not assist in some cases, but lithiated acetonitrile adds to it efficiently to give a product from which further C-nucleoside analogs can be derived.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:777802 CAPLUS
DOCUMENT NUMBER: 139:277119
TITLE: Preparation of C-nucleosides as inhibitors of nucleoside phosphorylases and nucleosidases
INVENTOR(S): Furneaux, Richard Hubert; Schramm, Vern L.; Tyler, Peter Charles; Evans, Gary Brian
PATENT ASSIGNEE(S): Industrial Research Limited, N. Z.; Albert Einstein College of Medicine of Yeshiva University
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080620	A1	20031002	WO 2003-NZ50	20030325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110772	A1	20040610	US 2003-395636	20030324
US 7098334	B2	20060829		
CA 2480470	AA	20031002	CA 2003-2480470	20030325
AU 2003215969	A1	20031008	AU 2003-215969	20030325
EP 1490373	A1	20041229	EP 2003-745042	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005527544	T2	20050915	JP 2003-578374	20030325
PRIORITY APPLN. INFO.:			NZ 2002-517970 A	20020325
			WO 2003-NZ50 W	20030325

OTHER SOURCE(S): MARPAT 139:277119
IT 607389-23-1P 607389-24-2P 607389-25-3P
607389-26-4P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of C-nucleosides as inhibitors of nucleoside phosphorylases and nucleosidases)
RN 607389-23-1 CAPLUS
CN 2H-Pyrazolo[4,3-d]pyrimidine, 3-[(3aS,4S,6R,6aR)-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]tetrahydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrol-4-yl]-7-methoxy-2-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607389-24-2 CAPLUS
CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[7-amino-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]tetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607389-25-3 CAPLUS
CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[7-(benzoylamino)-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]tetrahydro-6-(hydroxymethyl)-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607389-26-4 CAPLUS
CN 5H-1,3-Dioxolo[4,5-c]pyrrole-5-carboxylic acid, 4-[(acetylthio)methyl]-6-[7-(benzoylamino)-2-(tetrahydro-2H-pyran-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aR,4S,6S,6aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The present invention relates to compds. of the general formula I, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH2, NHR1, NR1R2 and SR3, where R1-R3 are each optionally substituted alkyl, aralkyl or aryl groups; B is selected from NH2 and NHR4, where R4 is an optionally substituted alkyl, aralkyl or aryl group; X is selected from H, OH and halogen; and Z is selected from H, Q, SQ and OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof; with the proviso that the stereochem. of the aza-sugar moiety is D-ribo- or 2'-deoxy-D-erythro-, which are inhibitors of 5'-methylthioadenosine phosphorylases and 5'-methylthioadenosine nucleosidases (MTAP and MTAN), the invention also relates to the use of these compds. in treatment of diseases and infections including cancer, bacterial infections and parasitic infections, and to pharmaceutical compns. containing the compds. Thus, I (X = OH, Z = SPh, A = CH, B = NH2) was prepared and tested in vitro as MTAP and MTAN inhibitor (Ki = 46 ± 3 pM and 890.0 ± 120 pM resp.).

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.01	193.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 09:55:14 ON 15 SEP 2006